Difference between revisions of "Non-alcoholic fatty liver disease historical perspective"

Jump to: navigation, search
(Historical Perspective)
(Overview)
Line 4: Line 4:
 
   
 
   
 
==Overview==
 
==Overview==
NAFLD/NASH was first described in a 1980 series of [[obese]], non-alcoholic patients of the [[Mayo Clinic]].<ref>Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55:434-438. PMID 7382552.</ref> Since that seminal description, our understanding of [[NAFLD]] has progressed minimally. <ref>Day, CP. Non-alcoholic steatohepatitis (NASH): where are we now and where are we going? Gut. 2002 May; 50(5): 585–588.</ref>
+
NAFLD/NASH was first described in a 1980 series of [[obese]], non-alcoholic patients of the [[Mayo Clinic]].<ref>Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55:434-438. PMID 7382552.</ref> Since that seminal description, our understanding of [[NAFLD]] has progressed minimally. <ref>Day, CP. Non-alcoholic steatohepatitis (NASH): where are we now and where are we going? Gut. 2002 May; 50(5): 585–588.</ref>The significance of NAFLD cannot be overstated. It parallels the obesity epidemic inside the US and is the most common hepatic disorder within the western hemisphere. currently the third leading indication for liver transplant, by 2030, non-alcoholic steatohepatitis (NASH) is expected to become the maximum not unusual motive for transplantation in the US. With an explosion of novel healing procedures for hepatitis C virus and a relative paucity of remedy alternatives for the spectrum of fatty liver disease, plenty interest has grew to become closer to development of NASH disorder-modifying agents and noninvasive diagnostic equipment.<ref name="pmid285079292">{{cite journal |vauthors=Vizuete J, Camero A, Malakouti M, Garapati K, Gutierrez J |title=Perspectives on Nonalcoholic Fatty Liver Disease: An Overview of Present and Future Therapies |journal=J Clin Transl Hepatol |volume=5 |issue=1 |pages=67–75 |year=2017 |pmid=28507929 |pmc=5411359 |doi=10.14218/JCTH.2016.00061 |url=}}</ref>
  
 
==Historical Perspective==
 
==Historical Perspective==

Revision as of 21:46, 7 December 2017

Non-Alcoholic Fatty Liver Disease Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Non-Alcoholic Fatty Liver Disease from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case studies

Case #1

Non-alcoholic fatty liver disease historical perspective On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Non-alcoholic fatty liver disease historical perspective

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Non-alcoholic fatty liver disease historical perspective

CDC on Non-alcoholic fatty liver disease historical perspective

Non-alcoholic fatty liver disease historical perspective in the news

Blogs on Non-alcoholic fatty liver disease historical perspective

Directions to Hospitals Treating Non-alcoholic fatty liver disease

Risk calculators and risk factors for Non-alcoholic fatty liver disease historical perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Vamsikrishna Gunnam M.B.B.S[2]

Overview

NAFLD/NASH was first described in a 1980 series of obese, non-alcoholic patients of the Mayo Clinic.[1] Since that seminal description, our understanding of NAFLD has progressed minimally. [2]The significance of NAFLD cannot be overstated. It parallels the obesity epidemic inside the US and is the most common hepatic disorder within the western hemisphere. currently the third leading indication for liver transplant, by 2030, non-alcoholic steatohepatitis (NASH) is expected to become the maximum not unusual motive for transplantation in the US. With an explosion of novel healing procedures for hepatitis C virus and a relative paucity of remedy alternatives for the spectrum of fatty liver disease, plenty interest has grew to become closer to development of NASH disorder-modifying agents and noninvasive diagnostic equipment.[3]

Historical Perspective

  • First introduced in 1980, NAFLD is a quite new concept. [4]
  • It is divided into non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH) primarily based on histologic findings.
  • Biopsies of NAFL may also display macrovesicular steatosis with lobular and periportal irritation however do now not display cellular injury and fibrosis (steatohepatitis), which characterizes NASH. [5]
  • NAFL has in large part been taken into consideration benign, but recent cohort studies display a high hazard for development to NASH in as much as 44% on serial biopsies at 5 years.
  • NASH reasons modern fibrosis which could result in cirrhosis and hepatocellular cancer (HCC).

References

  1. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55:434-438. PMID 7382552.
  2. Day, CP. Non-alcoholic steatohepatitis (NASH): where are we now and where are we going? Gut. 2002 May; 50(5): 585–588.
  3. Vizuete J, Camero A, Malakouti M, Garapati K, Gutierrez J (2017). "Perspectives on Nonalcoholic Fatty Liver Disease: An Overview of Present and Future Therapies". J Clin Transl Hepatol. 5 (1): 67–75. PMC 5411359Freely accessible. PMID 28507929. doi:10.14218/JCTH.2016.00061. 
  4. Vizuete J, Camero A, Malakouti M, Garapati K, Gutierrez J (2017). "Perspectives on Nonalcoholic Fatty Liver Disease: An Overview of Present and Future Therapies". J Clin Transl Hepatol. 5 (1): 67–75. PMC 5411359Freely accessible. PMID 28507929. doi:10.14218/JCTH.2016.00061. 
  5. Zhao ZH, Liu XL, Fan JG (2017). "[Research on the natural history of non-alcoholic fatty liver disease should be taken seriously]". Zhonghua Gan Zang Bing Za Zhi (in Chinese). 25 (2): 81–84. PMID 28297791. 

Linked-in.jpg